⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Home/Drugs/Abituzumab

Abituzumab

abituzumab

Phase 2a

Sponsor: Merck KGaA

Indication: SSc

Mechanism of Action

Anti-CD146 monoclonal antibody

Target: CD146

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

WITHDRAWNNCT03688230

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

Phase:PHASE2Org:SFJ Pharmaceuticals, Inc.

COMPLETED

Relevant Publications (PubMed)

Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets.

Bruschi A, Sambri A, Fiore M et al.

Cancer Med2025 May

Integration of NMR Spectroscopy in an Analytical Workflow to Evaluate the Effects of Oxidative Stress on Abituzumab: Beyond the Fingerprint of mAbs.

Cerofolini L, Ravera E, Fischer C et al.

Anal Chem2023 Jun 20

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.

Khanna D, Tashkin DP, Wells AU et al.

J Rheumatol2021 Aug

Integrins as A New Target for Cancer Treatment.

Validated Models

This drug has been validated in the following preclinical models:

NCT00848510

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Phase:PHASE1Org:Merck KGaA, Darmstadt, Germany

COMPLETEDNCT01008475

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Phase:PHASE1, PHASE2Org:Merck KGaA, Darmstadt, Germany

COMPLETEDNCT01360840

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Phase:PHASE2Org:EMD Serono

TERMINATEDNCT02745145

Abituzumab in SSc-ILD

Phase:PHASE2Org:EMD Serono

View all trials on ClinicalTrials.gov

Łasiñska I, Mackiewicz J

Anticancer Agents Med Chem2019

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP et al.

Rheumatology (Oxford)2019 Apr 1

View more on PubMed